Emprint™ Ablation System enables more certainty regardless of target
location or tissue type
DUBLIN, Ireland--(BUSINESS WIRE)--Jul. 16, 2014--
Overcoming a significant roadblock to predictable ablation of soft
plc (NYSE:COV) has unveiled an advanced ablation system that offers
physicians predictable results regardless of the target location or
tissue type. The Emprint™ Ablation System with Thermosphere™ Technology
is designed to precisely heat and destroy diseased soft tissue
(including liver, lung and kidney), and non-resectable liver tumors.
Liver tumor ablation with Emprint(TM) Ablation System can be performed without invasive surgery by inserting the system's antenna into the tumor directly through the skin. The physician utilizes ultrasound or CT scanning to guide the antenna. (Photo: Business Wire)
“Covidien is dedicated to improving patient safety and simplifying
procedural options, and this innovative technology enables physicians to
deliver precise ablation directly to soft tissue, including liver
tumors,” said Chuck Brynelsen, president, Early Technologies, Covidien.
“By providing predictable spherical ablation zones, this technology
gives physicians more choices in terms of approach, further simplifying
needle placement and saving planning and procedure time.”
Surgical removal of tumors may not be an optimal solution for some
patients. A liver tumor ablation procedure, which destroys liver tumors
without removing them, can be an alternative to open surgery resection
or other treatments.
The Emprint Ablation System provides clinicians three kinds of spatial
energy control – thermal, field and wavelength – to create predictable
and spherical ablation zones regardless of target location, tissue type,
or changes in tissue properties during a procedure.
Covidien’s advanced ablation system can be used in three different
procedure settings including non-surgical procedures directly through
the skin, minimally invasive surgery and open surgery.
Covidien received U.S. Food and Drug Administration 510(k) clearance for
Emprint Ablation System with Thermosphere Technology in April 2014. In
addition, Covidien completed all European requirements to CE Mark the
product. The company expects to fully launch the Emprint system in the
United States and the European Union during the current quarter. Please
to learn more about the Emprint Ablation System.
Covidien is a leading global health care products company that creates
innovative medical solutions for better patient outcomes and delivers
value through clinical leadership and excellence. Covidien develops,
manufactures and sells a diverse range of industry-leading medical
device and supply products. With 2013 revenue of $10.2 billion, Covidien
has more than 38,000 employees worldwide in more than 70 countries, and
its products are sold in over 150 countries. Please visit www.covidien.com
to learn more about our business.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140716005186/en/
John Jordan, 508-452-4891
Lannum, CFA, 508-452-4343